GetTopicDetailResponse(id=a37ee551709, topicName=突變負(fù)擔(dān), introduction=突變負(fù)擔(dān), content=null, image=null, comments=4, allHits=1197, url=https://h5.medsci.cn/topic?id=75517, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=77645, tagList=[TagDto(tagId=77645, tagName=突變負(fù)擔(dān))], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1864326, encodeId=53b41864326b0, content=<a href='/topic/show?id=a37ee551709' target=_blank style='color:#2F92EE;'>#突變負(fù)擔(dān)#</a>, objectTitle=Nat Med：血源性腫瘤突變負(fù)擔(dān)作為非小細(xì)胞肺癌阿特珠單抗治療的生物標(biāo)志物, objectType=article, longId=724549, objectId=b40de24549be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b40de24549be, replyNumber=0, likeNumber=91, createdTime=2022-11-22, rootId=0, userName=zutt, userId=742793, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b40de24549be, moduleTitle=Nat Med：血源性腫瘤突變負(fù)擔(dān)作為非小細(xì)胞肺癌阿特珠單抗治療的生物標(biāo)志物, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b40de24549be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1864325, encodeId=51de18643258b, content=<a href='/topic/show?id=a37ee551709' target=_blank style='color:#2F92EE;'>#突變負(fù)擔(dān)#</a>, objectTitle=AJH：PD-L1 過表達(dá)與 JAK2-V617F 突變負(fù)擔(dān)相關(guān)，并與骨髓增殖性腫瘤中的 9p 單親二體性相關(guān)。, objectType=article, longId=293934, objectId=e987293934a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e987293934a7, replyNumber=0, likeNumber=85, createdTime=2022-12-23, rootId=0, userName=zutt, userId=742793, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e987293934a7, moduleTitle=AJH：PD-L1 過表達(dá)與 JAK2-V617F 突變負(fù)擔(dān)相關(guān)，并與骨髓增殖性腫瘤中的 9p 單親二體性相關(guān)。, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e987293934a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1864324, encodeId=618e186432483, content=<a href='/topic/show?id=a37ee551709' target=_blank style='color:#2F92EE;'>#突變負(fù)擔(dān)#</a>, objectTitle=Lancet Gastroen Hepatol：多種突變負(fù)擔(dān)及其他分子標(biāo)志物對結(jié)腸癌預(yù)后的影響, objectType=article, longId=142427, objectId=e55014242e8d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e55014242e8d, replyNumber=0, likeNumber=120, createdTime=2019-01-16, rootId=0, userName=zutt, userId=742793, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e55014242e8d, moduleTitle=Lancet Gastroen Hepatol：多種突變負(fù)擔(dān)及其他分子標(biāo)志物對結(jié)腸癌預(yù)后的影響, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e55014242e8d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1864323, encodeId=4bdc1864323b6, content=<a href='/topic/show?id=a37ee551709' target=_blank style='color:#2F92EE;'>#突變負(fù)擔(dān)#</a>, objectTitle=NEJM：納武單抗聯(lián)合易普利姆瑪可改善高突變負(fù)擔(dān)肺癌患者生存, objectType=article, longId=135592, objectId=71dd1355929f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71dd1355929f, replyNumber=0, likeNumber=109, createdTime=2018-12-31, rootId=0, userName=zutt, userId=742793, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71dd1355929f, moduleTitle=NEJM：納武單抗聯(lián)合易普利姆瑪可改善高突變負(fù)擔(dān)肺癌患者生存, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=71dd1355929f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
